2012-10-06 18:58:54 - New Pharmaceuticals market report from Global Markets Direct: "Liver Cancer - Pipeline Review, H2 2012"

Global Markets Direct's, 'Liver Cancer - Pipeline Review, Global Markets Direct's, 'Liver Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Cancer. Liver Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the

availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Liver Cancer.
* A review of the Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Liver Cancer pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468345_liver_cancer_pipeline_review_h2_2012. ..


Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Liver Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Liver Cancer
Liver Cancer Therapeutics under Development by Companies
Liver Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Liver Cancer Therapeutics - Products under Development by Companies
Liver Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Liver Cancer Therapeutics Development
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Tekmira Pharmaceuticals Corp.
Bavarian Nordic A/S
Kowa Company, Ltd.
MDRNA, Inc.
Pfizer Inc.
Silence Therapeutics plc.
MultiCell Technologies, Inc.
Northwest Biotherapeutics, Inc.
OXiGENE, Inc.
Curis, Inc.
Alnylam Pharmaceuticals, Inc
Transgene SA
Immuron Limited
Synta Pharmaceuticals Corp.
CrystalGenomics, Inc.
Chipscreen Biosciences Ltd
ERYtech Pharma
Provecs Medical GmbH
Jennerex Biotherapeutics, Inc.
Advenchen Laboratories, LLC
Onconova Therapeutics, Inc
MolMed S.p.A.
China Medical System Holdings Limited
Welichem Biotech Inc.
Oncolys BioPharma Inc.
Immunocore Limited.
Sirnaomics, Inc.
Viventia Biotechnologies Inc.
TRACON Pharmaceuticals, Inc.
KAHR medical Ltd.
Keystone Nano, Inc.
EOS S.p.A.
IkerChem S.L.
Liver Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
peretinoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Doxorubicin Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Doxorubicin Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tyroserleutide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin + Capecitabine + Cetuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Doxorubicin + Mitomycin C + Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xelox + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TACE + Sunitinib Malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Mitomycin + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Doxorubicin + Fluorouracil + Irinotecan + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Doxorubicin + Fluorouracil + Vincristine - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468345&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.